CME

00:05:45

Translating Evidence on TROP2-Directed ADCs Into...

CME ·

2026/07/16

Faculty: Tiffany Traina, MD, FASCO Faculty: Javier Cortes, MD, PhD This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety

en

00:04:45

Comparing First-Line TROP2-Directed ADCs in...

CME ·

2026/07/16

Faculty: Javier Cortes, MD, PhD This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and

en

00:04:30

Current Unmet Needs in First-Line Treatment of...

CME ·

2026/07/16

Faculty: Javier Cortes, MD, PhD This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and

en

00:11:45

Mechanism to Match: Choosing the Right VMAT2 Strategy...

CME ·

2026/07/15

Faculty: Karen E. Anderson, MD Faculty: Hubert H. Fernandez, MD This Podcast Plus discussion reviews how treatment for tardive dyskinesia can be individualized based on patient-specific goals and pharmacologic considerations. The program examines clinically relevant differences among VMAT2 inhibitors, including factors such as speed of response, durability, tolerability, and regimen simplicity. It also addresses treatment selection in the setting of polypharmacy, with attention to

en

00:13:15

No Patient With CKD Left Behind: New Horizons in...

CME ·

2026/07/14

Faculty: Brendon Neuen, MBBS, PhD Faculty: Katherine Tuttle, MD A growing body of evidence presented at ERA 2026 is reshaping the conversation around chronic kidney disease management, regardless of diabetes status. In this expert interview, Dr. Katherine Tuttle and Dr. Brendon Neuen examine emerging data on nonsteroidal mineralocorticoid receptor antagonists and discuss how recent findings may expand treatment considerations for patients with chronic kidney disease (CKD),

en

01:00:00

Moving Beyond Sleep: The Broader Connection Between...

CME ·

2026/07/13

Faculty: Roger McIntyre, MD Faculty: Emmanuel Mignot, MD, PhD Sleep and psychiatric disorders are often managed separately in clinical practice, leaving key biological mechanisms unaddressed and contributing to recurrent cycles of relapse. Overlapping factors, including orexin-driven arousal mechanisms, REM sleep abnormalities, limited use of validated screening tools, and incomplete differential diagnoses for hypersomnia, can further impair quality of life and outcomes. This

en

00:16:15

Optimizing Outcomes in Patients with FSGS: A...

CME ·

2026/07/13

Host: Jörg Latus, MD Faculty: Sayna Norouzi, MD Focal segmental glomerulosclerosis (FSGS) remains a challenging disease, with many patients progressing to kidney failure and experiencing substantial effects on quality of life. As the treatment landscape evolves, clinicians must understand how emerging therapies may influence disease management and patient outcomes.Join Drs. Jörg Latus and Sayna Norouzi as they review the latest evidence in FSGS, including clinical data supporting

en

01:14:30

Precision Through the Continuum: Applying...

CME ·

2026/07/07

Faculty: Susana Campos, MD, MPH Faculty: Robert Coleman, MD, FACOG Faculty: Debra Richardson, MD This chapterized online educational activity is designed to translate biomarker-driven evidence into practical decision-making across the ovarian cancer continuum. Through expert discussion, participants will apply biomarker insights to guide treatment strategies in both frontline maintenance and platinum-resistant settings. Faculty emphasize patient selection, sequencing

en

01:00:00

Closing the Gaps: Global Implementation of Lipid...

CME ·

2026/06/30

Faculty: Lina Badimón, MD, PhD Faculty: Michelle O’Donoghue, MD, MPH Faculty: Erin Michos, MD, MHS Faculty: Pam R. Taub, MD A new modular CME-accredited program designed to support clinicians in translating evolving lipid guidelines into everyday practice. Delivered as a 60-minute webcast, divided into chapters for convenience, it integrates U.S. and international perspectives and focuses on equitable cardiovascular care. The course highlights women-specific cardiovascular

en

00:16:15

From Prevalence to Practice: Practical Screening and...

CME ·

2026/06/24

Faculty: Jorge Plutzky, MD Faculty: Bradley Eilerman, MD, MHI With our current understanding of how prevalent hypercortisolism is in patients with difficult-to-manage cardiometabolic disease, the focus shifts to what might clinicians do differently in practice? Which patients should healthcare providers screen, and what straightforward testing methods can be used to detect and confirm hypercortisolism with confidence? Once identified, how might earlier intervention alter the course

en

00:17:15

Translating Evidence Into Action: Nonsteroidal MRAs...

CME ·

2026/06/23

Faculty: Muthiah Vaduganathan, MD, MPH Faculty: Koichiro Kinugawa, MD Faculty: Michael Böhm, MD In this panel discussion from the ESC Heart Failure Congress 2026, Drs. Muthu Vaduganathan, Michael Böhm, and Koichiro Kinugawa discuss the role of nonsteroidal MRAs in patients with HFmrEF and HFpEF. Using a clinical case, the faculty review evolving recommendations supporting finerenone as part of guideline-directed medical therapy, along with evidence from FINEARTS-HF and related

en

00:32:30

Reimagining Alzheimer's Care: The Advent of...

CME ·

2026/06/23

Faculty: Alireza Atri, MD, PhD Faculty: Raymond Scott Turner, MD, PhD Faculty: Dani Cabral, MD In this activity, Dr. Alireza Atri and Dr. Scott Turner discuss the evolving role of subcutaneous anti-amyloid monoclonal antibody therapy in early Alzheimer disease. The conversation compares intravenous and subcutaneous administration and focuses on maintenance dosing after 18 months of IV therapy, practical implications for patients and care partners, and the potential impact on

en

00:29:00

IBD Masterclass: Choosing the Right IBD Therapy - A...

CME ·

2026/06/15

Faculty: Florence Odufalu, MD Faculty: Ugonna Iroku, MD, MHS Join Drs. Odufalu and Iroku for this Patient-Clinician Connection, a case-based activity focused on optimizing management of inflammatory bowel disease. Through real-world patient dialogues in Crohn’s disease and ulcerative colitis, this program examines clinical and deep remission, along with treat-to-target principles to guide care. Faculty discuss decision-making around biologic de-escalation, as well as identification

en

00:07:30

Crossing Home Plate – Building a Winning Team Culture

CME ·

2026/06/08

Faculty: J.A. Randy Englert, MD, FACC Faculty: Matthew Malachowski, Pharm. D., MHA This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.Across

en

00:07:30

Turning the Double Play – Comprehensive Secondary...

CME ·

2026/06/08

Faculty: J.A. Randy Englert, MD, FACC Faculty: Matthew Malachowski, Pharm. D., MHA This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.Across

en

00:05:15

Leadoff Hitter – Spotting High-Risk Players

CME ·

2026/06/08

Faculty: J.A. Randy Englert, MD, FACC This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.Across the program, faculty highlight guideline-aligned

en

00:05:30

Swing for the Fences – LDL-C as the Power Hitter

CME ·

2026/06/08

Faculty: J.A. Randy Englert, MD, FACC Faculty: Matthew Malachowski, Pharm. D., MHA This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.Across

en

00:06:30

Extra Innings – Sustaining Victory Beyond the First Game

CME ·

2026/06/08

Faculty: J.A. Randy Englert, MD, FACC Faculty: Matthew Malachowski, Pharm. D., MHA This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.Across

en

00:06:00

Small Ball Wins Games – Combination Therapy for Goal...

CME ·

2026/06/08

Faculty: J.A. Randy Englert, MD, FACC Faculty: Matthew Malachowski, Pharm. D., MHA This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.Across

en

00:56:30

A Q-Challenge™ Replay: Advancing Precision Diagnosis...

CME ·

2026/06/04

Faculty: Maria Fleseriu, MD, FACE Faculty: Shlomo Melmed, MBChB Faculty: Elise M. Brett, MD, FACE This broadcast replay from AACE 2026 features an interactive, case-based Q-Challenge format focused on acromegaly. Participants engage with clinical scenarios designed to assess and reinforce diagnostic evaluation and treatment decision-making. The activity highlights key considerations in identifying acromegaly, interpreting clinical findings, and selecting appropriate management

en

All Episodes

Similar Podcasts

النشرة العلمية

مونت كارلو الدولية / MCD

Ciência

RFI Português

天方烨谈

基因频道

Quilo de Ciencia - Cienciaes.com

Jorge Laborda

The Field Guides

The Field Guides